Bayer will cap R&D budget at $4.1B

With R&D expenses expected to surge 13 percent this year at Bayer, Germany's largest drug company, CEO Marijn Dekkers is telling reporters that he plans to make sure the budget item flatlines at $4.1 billion for 2011. Dekkers also noted that he was concerned "whether society will be prepared to pay an appropriate price for innovations in the future." Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.